Flibanserin

Excerpt

Flibanserin, initially developed as an antidepressant, is the first medication approved by the U.S. Food and Drug Administration (FDA) for the management of hypoactive sexual desire disorder (HSDD) in premenopausal women. HSDD is characterized by limited or absent sexual fantasies or desires, resulting in interpersonal strain or heightened distress, which persist for a minimum of 6 months. Flibanserin is specifically indicated for patients whose diagnosis is unrelated to relationship issues, psychiatric or medical conditions, or the effects of medication or drugs. Recent trials involving premenopausal women who have endured HSDD for a minimum of 6 months have further reinforced the drug's potential as a practical therapeutic option. This makes flibanserin a pivotal choice for premenopausal women experiencing primary HSDD. This activity covers flibanserin's indications, contraindications, mechanism of action, administration, monitoring, and toxicity. This activity aims to enhance collaboration among healthcare professionals for improved management of HSDD in patients using flibanserin, ultimately leading to more effective patient care and superior outcomes.